Director, Obesity Early Pipeline Commercial Development

ROLE SUMMARY

Obesity is one of the most exciting and dynamic areas in medicine today, and Pfizer's early obesity pipeline spans multiple mechanisms with the potential to help hundreds of millions of people living with obesity and its complications worldwide. The pace of scientific and competitive change in this space is unprecedented, creating a unique opportunity for a commercial leader to shape assets from their earliest stages.

The Director, Obesity Early Pipeline Commercial Development sits on the Obesity Global Commercial Strategy team within the Internal Medicine / Primary Care business unit, reporting to the Senior Director – Team Lead, Obesity Early Pipeline Commercial Development. The role is accountable for commercial development across a portfolio of early- and mid-stage assets spanning the chronic weight management treatment landscape. The Director owns commercial assessments end-to-end for covered programs — building product concepts and Target Product Profiles, developing disease-area strategies, and directing the integration of forecasting, pricing, HCP demand, future landscaping, and patient-flow insights into actionable commercial plans.

Operating as a cross-functional leader without direct line authority, the Director interprets business unit strategy to set priorities for covered programs, shapes early development strategy in partnership with R&D, advances assets through enterprise governance, and leads select strategic initiatives spanning the broader obesity portfolio. The role requires a strong sense of urgency, comfort operating in ambiguity and white space, the ability to translate emerging science and market signals into investment cases, and a regular cadence of engagement with senior leadership.

The Director may manage consultants, growth gigs, etc. in support of these objectives.